A review of renal GH/IGF1 family gene expression in chronic kidney diseases

Brittain, Alison; Kopchick, John J.

doi:10.1016/j.ghir.2019.07.001

Cited by 6 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within our MKA-based meta-markers for PTS3T2 , we identified previously known markers, such as Slc22a13 , as well as novel markers: Ghr or Mep1b ( Figure S10 A). Ghr has been previously associated with chronic kidney disease, 38 whereas Mep1b plays a role in acute kidney injury, with Mep1b −/− mice showing improved renal function compared to WT mice. 39 We compared the expression of the top five PTS3T2 meta-markers with the top five PTS3T2 differentially expressed genes in the MKA ( Figure 5 C and Table S4 ).…”

Section: Resultsmentioning

confidence: 99%

A comprehensive mouse kidney atlas enables rare cell population characterization and robust marker discovery

et al. 2023

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

A comprehensive mouse kidney atlas enables rare cell population characterization and robust marker discovery

et al. 2023

View full text Add to dashboard Cite

“…Past research has revealed that under the condition of different chronic kidney diseases, including DKD, the expression level of renal GHR was decreased both in humans and in rodents. And the increase of GHR level was associated with the increase of GFR and the decrease of serum creatinine [ 22 ]. However, there are also a few converse opinions.…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of immune-related biomarkers and potential regulators and therapeutic targets for diabetic kidney disease

Chen

et al. 2023

BMC Med Genomics

View full text Add to dashboard Cite

Background Diabetic kidney disease (DKD) is a major complication of diabetes and the leading cause of end-stage renal disease worldwide. Renal inflammation and infiltration of immune cells contribute to the development and progression of DKD. Thus, the aim of the present study was to identify and validate immune-related biomarkers and analyze potential regulators including transcription factors (TFs), microRNAs (miRNAs), and drugs for DKD. Methods Immune-related genes from the ImmPort database and glomeruli samples from GSE1009 and GSE30528 were used to identify differentially expressed immune-related genes (DEIRGs) of DKD. The expression level and clinical correlation analyses of DEIRGs were verified in the Nephroseq database. Murine podocytes were cultured to construct the high glucose-induced podocyte injury model. The reliability of the bioinformatics analysis was experimentally validated by RT-qPCR in podocytes. Networks among DEIRGs, regulators, and drugs were constructed to predict potential regulatory mechanisms for DKD. Results DKD-associated DEIRGs were identified. CCL19 and IL7R were significantly upregulated in the DKD group and negatively correlated with glomerular filtration rate (GFR). GHR, FGF1, FYN, VEGFA, F2R, TGFBR3, PTGDS, FGF9, and SEMA5A were significantly decreased in the DKD group and positively correlated with GFR. RT-qPCR showed that the relative mRNA expression levels of GHR, FGF1, FYN, TGFBR3, PTGDS, FGF9, and SEMA5A were significantly down-regulated in the high glucose-induced podocyte injury group. The enriched regulators for DEIRGs included 110 miRNAs and 8 TFs. The abnormal expression of DEIRGs could be regulated by 16 established drugs. Conclusions This study identified immune-related biomarkers, regulators, and drugs of DKD. The findings of the present study provide novel insights into immune-related diagnosis and treatment of DKD.

show abstract

“…IGFBP-6 is a glycoprotein secreted from various tissues that regulate cell proliferation, differentiation, and survival by binding to IGF or inducing apoptosis independently [16]. Increased expression of IGFBP-6 has been observed in the kidney in certain renal diseases such as FSGS, IgA nephropathy, and lupus nephritis [17]. IGFBP-6 levels in the serum may also increase in kidney diseases, potentially due to upregulation of its gene and reduced renal clearance, and decrease after transplantation [18].…”

Section: Discussionmentioning

confidence: 99%

A Urinary Proteomics Approach to Predict Treatment Response in Acute Antibody-Mediated Rejection

Heidari,

Dalili,

Samavat

et al. 2023

OBM Transplant

View full text Add to dashboard Cite

Acute antibody-mediated rejection (AMR) is a severe complication affecting kidney allografts' long-term survival. Timely detection and appropriate treatment of AMR are crucial for improving graft outcomes. This study aimed to discover non-invasive urinary biomarkers that can predict the response to therapy in patients with AMR. Materials and Methods: In this case-control study, urine samples from 21 biopsy-proven AMR patients underwent proteomics using label-free quantification. The patients were divided into two groups: responders and non-responders to treatment based on their graft function. Urinary proteins were identified, and their expressions were compared between the two groups to identify potential candidate biomarkers. Out of the 1020 identified proteins, 257 proteins were found to be differentially expressed between the two groups. Among these, 153 proteins showed increased expression in non-responder patients, while 104 proteins showed decreased expression. Non-responder patients exhibited higher activation of complement pathway and extracellular matrix degradation than responders. Insulin-like growth factor binding protein 6 (IGFBP-6) emerged as the most sensitive and specific biomarker for predicting non-response to treatment in patients with AMR. Our study has successfully identified urinary proteome biomarkers that can distinguish and predict non-responder patients with AMR. These biomarkers are associated with various biological processes that reflect the pathogenesis and severity of AMR. Further research is necessary to validate these findings.

show abstract

A review of renal GH/IGF1 family gene expression in chronic kidney diseases

Cited by 6 publications

References 45 publications

A comprehensive mouse kidney atlas enables rare cell population characterization and robust marker discovery

A comprehensive mouse kidney atlas enables rare cell population characterization and robust marker discovery

Identification and validation of immune-related biomarkers and potential regulators and therapeutic targets for diabetic kidney disease

A Urinary Proteomics Approach to Predict Treatment Response in Acute Antibody-Mediated Rejection

Contact Info

Product

Resources

About